Shire (SHP.L) said cheap, copycat competition would have only a limited impact on sales of its hyperactivity drugs in the key back-to-school period, reassuring investors that earnings would still rise by a double-digit percentage this year. Shares in the pharmaceutical company, which fell as much as 13 percent in June when U.S. regulators approved a cut-price version of Adderall XR, rose more than 7 percent on Wednesday after it gave the earnings target along with a beat for the second quarter.
